Demo Data from EDBT 2026 / reviewers in the wild / expert
David Powers
dblp:27/3055
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2000
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Systems, architecture and hardware · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Computer architecture, parallel and distributed computing, and storage systems
1 paper |
Parallel and multicore computing · 100% | |
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Parallel and multicore computing › parallel computing
parallel application performance |
0.0 | 1 | 2000 | Data Access Performance in a Large and Dynamic Pharmaceutical Drug Candidate Database · SC 2000 |
Bioinformatics and computational biology › molecular informatics
cheminformatics |
0.0 | 1 | 2000 | Data Access Performance in a Large and Dynamic Pharmaceutical Drug Candidate Database · SC 2000 |
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2000 | Data Access Performance in a Large and Dynamic Pharmaceutical Drug Candidate DatabaseabstractAn explosion in the amount of data generated through chemical and biological experimentation has been observed in recent years. This rapid proliferation of vast amounts of data has led to a set of cheminformatics and bioinformatics applications that manipulate dynamic, heterogeneous, and massive data. An example of such applications in the pharmaceutical industry is the computational process involved in the early discovery of lead drug candidates for a given target disease. This computational process includes repeated sequential and random accesses to a drug candidate database. Using the above pharmaceutical application, an experimental study was conducted in this paper that shows that for optimal performance, the degree of parallelism exploited in the application should be adjusted according to the drug candidate database instance size and the machine size. Additionally, different degrees of parallelism should be used depending on whether the access to the drug candidate database is random or sequential. Zina Ben-Miled, Yang Liu 0031, David Powers, Omran A. Bukhres, Michael Bem, Robert J. Oppelt, Samuel Milosevich |
SC | 3 |